Sport MorphoSys share wins: MorphoSys exceeds forecasts for 2020 with sales and EBIT
Beiersdorf share gives way before the market: Beiersdorf earns less - dividend unchanged
Beiersdorf made less sales and earned disproportionately less in the past fiscal year. © Provided by Finanz.net DANIEL ROLAND / AFP / Getty Images All divisions felt the lower demand due to the corona, especially the sun protection division and the luxury cosmetics brand La Prairie suffered from travel restrictions to curb the further spread of the COVID-19 virus.
Despite the corona pandemic, the biotech company MorphoSys performed better than it expected last year.
Thecompany benefited from the share in the sales of the psoriasis agent Tremfya from the Danish partner Janssen.
According to preliminary calculations, the management now expects earnings before interest and taxes (EBIT) of EUR 27.4 million for the full year 2020, aslate on Monday evening. The target was significantly less at 10 to 20 million euros. At 327.7 million euros, sales are likely to be slightly above the upper end of the forecast range of 317 to 327 million euros.
Gerresheimer increases dividend after growth
A high demand from the pharmaceutical industry for glass ampoules and syringes gave the special packaging manufacturer Gerresheimer tailwind at the end of 2020. © Provided by Finanz.net Ralph Orlowski / Getty Images "In the fourth quarter, Gerresheimer was able to post its first significant sales revenues from the manufacture and delivery of injection vials for Covid-19 vaccines," said the statement published on Thursday Annual result.
Sales are likely to have more than quadrupled compared to the previous year, after MorphoSys had made just under 72 million euros in 2019. In addition, the Bavarian company managed to make the leap back into the black in day-to-day business after four years of losses: In 2019, the EBIT was still a minus of just under 108 million euros on the books.
At the same time, MorphoSys stepped up its research and development efforts last year: The costs for this are expected to be EUR 141.4 million and thus slightly above the forecast range of EUR 130 to 140 million.
analysts reacted positively to the first key figures on Tuesday: The key data for sales and the operating result (EBIT) were above company targets and expectations, wrote Goldman analyst Graig Suvannavej. Barclays analyst Rosie Turner praised that the antibody specialist ended the previous year strong. On the stock exchange, MorphoSys shares recently climbed 2.55 percent to EUR 87.72 in early trading via XETRA. However, since its annual high at the end of January at almost EUR 102, the paper has lost around 16 percent of its value to date.
Covid Death Outlook Improves as Drop in U.S. Exceeds Forecasts
The decline in Covid-19 fatalities is exceeding expectations in the U.S., and virus modelers are revising forecasts to reflect a more optimistic outlook heading into March. The country is expected to have about 7,922 such deaths in the week ending March 20, the lowest since the first week of November, according to the University of Massachusetts’ Reich Lab Covid-19 Forecast Hub, which issued a 28-day forecast on Tuesday based on dozens of independent models.The Reich Lab’s contributors sharply cut projections for the coming three weeks after deaths last week came in at 4,318 fewer than expected.
The jump in sales last year was largely due to high prepayments from the US company Incyte, which had secured the sole marketing rights outside the US for the cancer drug Monjuvi. For the time being, however, the drug is only approved in the United States. Monjuvi is the first own product and the greatest hope of the German antibody specialist, who had only worked for other companies for a long time. In the USA, MorphoSys is marketing the drug together with its partner Incyte. According to the current information, MorphoSys received 22 million US dollars from this last year - the equivalent of around 18.5 million euros.
The blood cancer therapy was only approved in the USA in mid-August in combination with the drug lenalidomide as a so-called second-line therapy for a special blood cancer. In the few remaining weeks of the third quarter, the drug MorphoSys had already brought in more than four million euros. As a result, Monjuvi sales are likely to have accelerated further in the fourth quarter and were around 14 million euros.
MorphoSys had already raised its annual forecasts at the end of October due to the market launch of Monjuvi, and the Management Board had also justified its goals at that time with a higher share of the sales of the psoriasis product Tremfya. According to the preliminary calculations, these royalties are likely to have been 42.5 million euros last year - around 13 percent of group sales. The drug Tremfya from the Johnson & Johnson subsidiary Janssen is based on an antibody from MorphoSys.
MorphoSys plans to publish its final figures for 2020 on March 15. / tav / mne / stkPLANEGG / MÜNCHEN (dpa-AFX)
Relaxing restrictions, Food Night, mass vaccine sites: News from around our 50 states .
How the COVID-19 pandemic is affecting every stateStart the day smarter. Get all the news you need in your inbox each morning.